Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Nephrology  |  Family Medicine  |  Urology

Search Medical Condition
Please enter condition
Please choose location from dropdown

Peyronie's Disease Clinical Trials

A listing of Peyronie's Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (5) clinical trials

Phase 4, Single-Center, Multiple Dose, Open-Label Trial to evaluate the Efficacy of Additional Xiaflex Treatment in Patients with Peyronie's Disease Recurrence, Worsening, or Incomplete Response after Prior Xiaflez Treatment  

Phase N/A

H-22411: BOTOX for Peyronie's Disease

Treatments for this disease have been limited and often unsuccessful. The goal of treatment is to reduce pain and maintain sexual function. Oral medicines that prevent plaque formation and promote plaque breakdown have not been effective. Many patients with the disease will require injections of medicines directly into the plaque. ...


Low-Intensity Extracorporeal Shockwave Therapy and Vacuum Erectile Device as a Treatment for Peyronies Disease.

Aim The primary aim is to examine whether LI-ESWT and vacuum erectile device (VED) followed by manipulation exercises has beneficial effect on PD patients compared to a placebo group. Primary Outcome Peyronie's Disease Questionnaire (PDQ) Visual Analogue Scale score (VAS) International Index of Erectile Function 5 (IEFF-5) Penile curve measurements ...

Phase N/A

Additional Xiaflex Treatment in Patients With Peyronie's Disease Recurrence Worsening or Incomplete Response

Subjects who have had an incomplete response to previous Xiaflex will receive up to 4 additional cycles of treatment.


Treatment Response to Xiaflex for Men With Peyronie's Disease

Xiaflex, Collagenase Clostridium histolyticum (CCH) is the only FDA approved medical treatment for correcting penile curvature associated with Peyronie's disease. Xiaflex is efficacious in approximately 60% of patients with an average improvement in penile curvature of 17 degrees as defined by global response assessment. Identifying predictors of Xiaflex non-response is ...